Cinieri, S. Et Al. 2017. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer. CLINICAL BREAST CANCER , vol.17, no.2 , 91-99.

Cinieri, S., Chan, A., Altundag, K., Vandebroek, A., Tubiana-Mathieu, N., Barnadas, A., ... Dodyk, P.(2017). Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer. CLINICAL BREAST CANCER , vol.17, no.2, 91-99.

Cinieri, Saverio Et Al. "Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer," CLINICAL BREAST CANCER , vol.17, no.2, 91-99, 2017

Cinieri, Saverio Et Al. "Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer." CLINICAL BREAST CANCER , vol.17, no.2, pp.91-99, 2017

Cinieri, S. Et Al. (2017) . "Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer." CLINICAL BREAST CANCER , vol.17, no.2, pp.91-99.

@article{article, author={Saverio Cinieri Et Al. }, title={Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer}, journal={CLINICAL BREAST CANCER}, year=2017, pages={91-99} }